News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Columbia Laboratories, Inc. (CBRX) Signs U.S. License and Supply Agreement with ASCEND Therapeutics, Inc. to Market PROCHIEVE(R) 4% Progesterone Gel



9/27/2007 9:49:18 AM

LIVINGSTON, N.J.--(BUSINESS WIRE)--Columbia Laboratories, Inc. (NASDAQ: CBRX) today announced that it has signed an exclusive, five year license and supply agreement with Ascend Therapeutics, Inc., for the Company’s PROCHIEVE ® 4% progesterone gel, currently indicated and FDA-approved for the treatment of secondary amenorrhea (secondary amenorrhea is lack of periods for six or more months in a woman who has already started menstruation and who is not pregnant, lactating, or in menopause).

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES